How to buy Matinas BioPharma stock (MTNB)

Matinas BioPharma is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.55 – a decrease of 4.05% over the previous week. Matinas BioPharma employs 32 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Matinas BioPharma stock

Buy Matinas BioPharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Matinas BioPharma stock price (NYSE MKT: MTNB)

Use our graph to track the performance of MTNB stocks over time.

Matinas BioPharma shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.55
52-week range	$0.50 - $18.49
50-day moving average more info button	$1.54
200-day moving average more info button	$6.55
Wall St. target price	$30.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.74

Is it a good time to buy Matinas BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Matinas BioPharma price performance over time

Historical closes compared with the close of $0.545 from 2024-12-20

1 week (2024-12-13)	-4.05%
1 month (2024-11-22)	-11.51%
3 months (2024-09-20)	-85.23%
6 months (2024-06-21)	254.13%

1 year (2023-12-22)	148.86%
2 years (2022-12-22)	-97.82%
3 years (2021-12-22)	53.5
5 years (2019-12-20)	85.5

Matinas BioPharma financials

Gross profit TTM	$-13,490,000
Return on assets TTM	-50.87%
Return on equity TTM	-97.59%
Profit margin	0%
Book value	$4.43
Market Capitalization more info button	$3 million

TTM: trailing 12 months

Matinas BioPharma share dividends

We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.

Have Matinas BioPharma's shares ever split?

Matinas BioPharma's shares were split on a 1:50 basis on 2 September 2024 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Matinas BioPharma shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Matinas BioPharma shares which in turn could have impacted Matinas BioPharma's share price.

Matinas BioPharma share price volatility

Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.5 up to $18.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 1.728. This would suggest that Matinas BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Matinas BioPharma overview

Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.

Frequently asked questions

What percentage of Matinas BioPharma is owned by insiders or institutions?
Currently 2.49% of Matinas BioPharma shares are held by insiders and 26.084% by institutions. How many people work for Matinas BioPharma?
Latest data suggests 32 work at Matinas BioPharma. When does the fiscal year end for Matinas BioPharma?
Matinas BioPharma's fiscal year ends in December. Where is Matinas BioPharma based?
Matinas BioPharma's address is: 1545 Route 206 South, Bedminster, NJ, United States, 07921 What is Matinas BioPharma's ISIN number?
Matinas BioPharma's international securities identification number is: US5768101058 What is Matinas BioPharma's CUSIP number?
Matinas BioPharma's Committee on Uniform Securities Identification Procedures number is: 576810105